Somewhat Positive Press Coverage Somewhat Unlikely to Impact ANI Pharmaceuticals (ANIP) Share Price

Media coverage about ANI Pharmaceuticals (NASDAQ:ANIP) has been trending somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ANI Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 45.4477693559278 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have effected Accern’s analysis:

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded down 0.11% during mid-day trading on Friday, hitting $44.01. 69,106 shares of the stock traded hands. The firm has a market cap of $512.19 million, a price-to-earnings ratio of 96.30 and a beta of 3.08. ANI Pharmaceuticals has a 12-month low of $42.23 and a 12-month high of $70.92. The firm’s 50 day moving average price is $46.91 and its 200 day moving average price is $50.31.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.19. The company had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $43.20 million. ANI Pharmaceuticals had a return on equity of 22.70% and a net margin of 3.35%. The firm’s quarterly revenue was up 43.0% compared to the same quarter last year. During the same period last year, the business posted $1.11 earnings per share. On average, equities research analysts predict that ANI Pharmaceuticals will post $3.84 EPS for the current fiscal year.

A number of research firms have issued reports on ANIP. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 3rd. Canaccord Genuity began coverage on shares of ANI Pharmaceuticals in a research note on Monday, July 31st. They issued a “buy” rating and a $60.00 price objective on the stock. Roth Capital set a $56.00 price objective on shares of ANI Pharmaceuticals and gave the stock a “hold” rating in a research note on Saturday, May 6th. Guggenheim reiterated a “buy” rating and issued a $80.00 price objective on shares of ANI Pharmaceuticals in a research note on Tuesday, July 4th. Finally, ValuEngine lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. ANI Pharmaceuticals has a consensus rating of “Hold” and an average target price of $65.33.

WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact ANI Pharmaceuticals (ANIP) Share Price” was published by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Leave a Reply